SCHEDULE: Capital International Investors Reports Zero Ownership in NovoCure Ltd.

Sentiment:

Beneficial Ownership Disclosure 7 July 2025 1:42 PM

Capital International Investors has filed an amended Schedule 13G, indicating it no longer holds any beneficial ownership in NovoCure Ltd.'s common stock as of June 30, 2025.

Worse than expectedCapital International Investors, a significant institutional investor, has reported 0% beneficial ownership in NovoCure Ltd., indicating a complete divestment or a reduction below the reporting threshold, which is typically viewed negatively by the market.

Summary

Capital International Investors (CII) filed an Amendment No. 5 to Schedule 13G regarding NovoCure Ltd.'s common stock.
CII reported beneficial ownership of 0 shares of NovoCure Ltd. common stock.
This represents 0.0% of the 111,485,634 shares believed to be outstanding by Capital International Investors.
The filing date is July 3, 2025, with the event date requiring the filing being June 30, 2025.
Capital International Investors is classified as an investment adviser.

Sentiment

Score: 3

Explanation: The filing indicates that Capital International Investors, a significant institutional investor, no longer holds any beneficial ownership in NovoCure Ltd., which can be perceived as a negative signal by the market.

Negatives

Capital International Investors, a significant institutional investor, has reduced its beneficial ownership in NovoCure Ltd. to 0 shares, representing 0.0% of the outstanding common stock.

Future Outlook

No forward-looking statements or guidance regarding NovoCure Ltd.'s operations or financial performance are provided in this beneficial ownership disclosure.

Industry Context

This filing is a routine disclosure of an institutional investor's stake and does not provide broader industry trends or competitive analysis for NovoCure Ltd.'s sector.

Stakeholder Impact

Shareholders: May react negatively to the news of a major institutional investor divesting its entire stake, potentially leading to a decrease in share price.

Key Dates

Date	Description
06/30/2025	Date of event requiring the filing of this statement.
07/03/2025	Date of filing of this Schedule 13G Amendment No. 5.

Recommendation

sell

Keywords

NovoCure Ltd., Capital International Investors, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, G6674U108

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.